Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  oxaliplatin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 539 for your search:
Start Over
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000574159, CHUL-BIO-COLON, INCA-RECF0356, RECF0356, NCT00559676
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML21380, NCT00577031
Combination Chemotherapy in Treating Older Patients With Solid Tumour,
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 75 and over
Sponsor: Other
Protocol IDs: CDR0000593133, GERCOR-OLD, EudraCT-2007004103-36, GERCOR-OLD07-SA07-1, NCT00664911
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25753, NCT01588990
Phase II/III Randomized Study of Fluorouracil/Leucovorin with vs without Oxaliplatin for Inoperable Metastatic Colorectal Cancer (Summary Last Modified 03/98)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: FRE-DEB95-OXA-01, EU-96023
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000430100, FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 04458, P30CA082103, UCSF-04458, NCT00227617
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000453890, GERCOR-OPTIMOX2, GERCOR-OPTIMOX2-2003, GERCOR-OPTIMOX2-C02-2, EU-20566, SANOFI-GERCOR-OPTIMOX2, NCT00274872
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000470411, FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00013, Eudract Number 2005-003440-66, NCT00384176
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595050, FRE-FNCLCC- ACCORD-17-0707, EU-20848, NCT00861094
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: GIHSYSU01, NCT01211210
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: FLOT4, NCT01216644
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000066151, FRE-GERCOR-C97-3/CPTF308, FRE-C97-3/CPTF301, FRE-C97-3/CPTF308, RP-FRE-C97-3/CPTF308, EU-97044, NCT00003260
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: EORTC-05963, NCT00003287
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066665, NCCTG-N9741, CAN-NCIC-CO13, CLB-89804, E-N9741, SWOG-N9741, N9741, CO13, NCT00003594
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01847, N9841, SWOG-N9841, NCCTG-N9841, CDR0000067623, ECOG-N9841, U10CA025224, NCT00005036
Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000068282, FRE-GERCOR-OPTIMOX-2000, EU-20034, NCT00006468
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000068309, EORTC-40983, AGITG-EORTC-40983, ALM-CAO-EORTC-40983, CRUK-LON-EORTC-40983, FFCD-EORTC-40983, EU-20048, CRC-EORTC-40983, NCT00006479
Start Over